BIUSTRE

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

Show simple item record

dc.contributor.author Makubate, Boikanyo
dc.contributor.author Donnan, Peter
dc.contributor.author Dewar, John
dc.contributor.author Thompson, Andrew
dc.contributor.author McCowan, Colin
dc.date.accessioned 2026-03-16T10:22:52Z
dc.date.available 2026-03-16T10:22:52Z
dc.date.issued 2013-03-21
dc.identifier.citation Makubate,B, et al. (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality,British Journal of Cancer (2013) 108, 1515–1524 | doi: 10.1038/bjc.2013.116 en_US
dc.identifier.uri https://repository.biust.ac.bw/handle/123456789/735
dc.description.abstract Background: Adjuvant endocrine therapy is recommended for women with oestrogen receptor-positive breast cancer, but many women do not take the medication as directed and they stop treatment before completing the standard 5-year duration. Methods: This retrospective cohort study conducted between 1993 and 2008 of all women with incident breast cancer, who are residing in the Tayside region of Scotland, examined adherence to prescribed adjuvant tamoxifen or aromatase inhibitors (AIs). Survival analysis examined the effect of adherence on all-cause mortality, breast cancer death and recurrence, using linked prescribing, cancer registry, clinical cancer audit, hospital discharge and death records. Results: A total of 3361 women with breast cancer were followed for a median 4.47 years (interquartile range (IQR) ¼ 2.04–8.55). The median overall adherence was 90% (IQR ¼ 90–100%), but the annual adherence reduced after a longer period from diagnosis. Low adherence of o80% was associated with poorer survival (hazard ratios ¼ 1.20; 95% confidence interval ¼ 1.03–1.40, P ¼ 0.019). There was no significant difference for low adherence over the treatment period and recurrence, or breast cancer death, but patients with high annual adherence for 5 years had better outcomes than those with 3 or less. Conclusion: Low adherence to all adjuvant endocrine therapy for women with breast cancer, whether tamoxifen or AI, increases the risk of death. en_US
dc.publisher British Journal of Cancer en_US
dc.subject Breast cancer en_US
dc.subject Tamoxifen en_US
dc.subject Aromatase inhibitors en_US
dc.subject Adherence en_US
dc.subject Mortality en_US
dc.subject Recurrence en_US
dc.title Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality en_US
dc.description.level phd en_US
dc.description.accessibility unrestricted en_US
dc.description.department mss en_US


Files in this item

Icon
Name: Makubate, B_British ...
Size: 200.5Kb
Format: PDF
View/Open

This item appears in the following Collection(s)

  • Faculty of Sciences
    This collection is made up of electronic theses and dissertations produced by post graduate students from Faculty of Sciences

Show simple item record

Search BIUSTRE


Browse

My Account